اَخر الأخبار
Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could support broader market adoption and strengthen Biocon’s position in the biosimilars segment.
For more details: Click here